BCRX Biocryst Pharmaceuticals Inc

Price (delayed)

$9.55

Market cap

$2.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$3.12B

?
Relative Growth: Rel. Growth: 73
Relative Strength: Rel. Strength: 69
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 19

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in ...

Highlights
Biocryst Pharmaceuticals's gross profit has soared by 70% YoY and by 6% from the previous quarter
BCRX's revenue has soared by 69% YoY and by 6% QoQ
BCRX's equity is up by 18% since the previous quarter but it is down by 8% year-on-year
BCRX's debt is up by 13% YoY but it is down by 2.5% QoQ

Key stats

What are the main financial stats of BCRX

BCRX stock price

How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-1.14%
1 week
-1.95%
1 month
1.38%
1 year
13.96%
YTD
22.44%
QTD
-4.5%

Financial performance

How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$940.61M
Gross profit
$919.69M
Operating income
-$313.16M
Net income
-$384.67M
Gross margin
97.8%
Net margin
-40.9%
Biocryst Pharmaceuticals's gross profit has soared by 70% YoY and by 6% from the previous quarter
BCRX's revenue has soared by 69% YoY and by 6% QoQ
The operating margin has grown by 23% from the previous quarter
BCRX's net margin is up by 21% QoQ

Price vs fundamentals

How does BCRX's price correlate with its fundamentals

Growth

What is Biocryst Pharmaceuticals's growth rate over time

Valuation

What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
2.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.32
BCRX's EPS is up by 17% from the previous quarter
BCRX's equity is up by 18% since the previous quarter but it is down by 8% year-on-year
BCRX's revenue has soared by 69% YoY and by 6% QoQ
The P/S is 60% lower than the 5-year quarterly average of 6.5 but 3.2% higher than the last 4 quarters average of 2.5

Efficiency

How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS is up by 24% from the previous quarter
The ROIC rose by 22% QoQ
The company's return on assets rose by 20% QoQ

Dividends

What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCRX.

Financial health

How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 45% lower than its total liabilities
Biocryst Pharmaceuticals's quick ratio has increased by 25% QoQ and by 12% YoY
Biocryst Pharmaceuticals's total assets has increased by 22% YoY and by 20% QoQ
BCRX's debt to equity is down by 19% since the previous quarter and by 5% year-on-year
BCRX's equity is up by 18% since the previous quarter but it is down by 8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.